Methods for treatment or prevention of damage resulting from radiation, trauma or shock
Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
1. A method of treating a subject identified as having been exposed to radiation, trauma, or shock, wherein the radiation, trauma, or shock results in gastrointestinal (GI) damage, the method comprising administering a therapeutically effective amount of a compound to the subject,
wherein the compound is a compound of Formula (I):
wherein:
n is an integer between 20 and 6000; and
each R 1 is independently selected for each occurrence from hydrogen, acetyl,
wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 2% of R 1 substituents
are
wherein upon administration of the compound, the compound treats, reduces the severity, or delays the onset of sepsis or reduces the likelihood of mortality in the subject, thereby treating the subject.
2. The method of claim 1 , wherein the subject has a bacterial infection, chemical damage or radiation damage.
3. The method of claim 2 , wherein the infection or damage results in leaky gut.
4. The method of claim 1 , wherein the method reduces the severity of sepsis or a symptom thereof or decreases the likelihood of mortality from the radiation, trauma or shock relative to a subject not administered with the compound.
5. The method of claim 1 , wherein the subject has sepsis or a symptom of sepsis resulting from radiation, trauma or shock.
6. The method of claim 1 , wherein the trauma or shock is a bacterial, viral, or fungal infection resulting in GI damage.
7. The method of claim 6 , wherein the bacterial infection is from one of the following bacteria: Salmonella enterica serovar Typhimurium, Shigella flexneri, E. Coli , and P. aeruginosa.
8. The method of claim 1 , wherein the method reduces inflammation in the subject from the radiation, trauma or shock in the subject.
9. The method of claim 1 , wherein the trauma results from exposure to a toxic chemical or poison.
10. The method of claim 1 , wherein the trauma results from multi-organ failure from physical damage and trauma to the body, burns, blast injury, systemic infection, blood loss (hypotension), or traumatic brain injury.
11. The method of claim 1 , wherein the shock results from excessive stimuli, commensals, injury, heat, autoantigens, tumors, or necrotic cells.
12. The method of claim 1 , wherein the subject has necrotizing enterocolitis, necrotic enteritis, short bowel syndrome, or short gut syndrome.
13. The method of claim 1 , wherein the compound is administered at regular intervals.
14. The method of claim 1 , wherein the subject is treated within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, or 2 weeks after exposure to radiation, trauma, shock, or infection.
15. The method of claim 1 , wherein the compound is functionalized at between 18% and 30%.
16. The method of claim 1 , wherein the molecular weight of the compound is from 50 to 150 kDa.
17. The method of claim 1 , wherein the polydispersity index of the compound is from 1.0 to 2.5.
18. A method of reducing permeability of the gastrointestinal tract of a subject identified as having been exposed to radiation trauma, or shock, the method comprising administering a therapeutically effective amount of a compound to the subject,
wherein the compound is a compound of Formula (I):
wherein:
n is an integer between 20 and 6000; and
each R 1 is independently selected for each occurrence from hydrogen, acetyl,
wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 2% of R 1 substituents
are
wherein upon administration of the compound, the compound reduces permeability of the gastrointestinal tract of a subject.
19. The method of 18 , wherein the permeability is a result of shock, trauma, or exposure to infection in the GI.